IL-6, IL-0, IFN Gamma and CRP in Newly Diagnosed COVID 19 Patients
Keywords:COVID-19; SARS COV2; IL-6; IFN gamma; CRP.
The study was conducted in Baghdad for the period from July 1 to August 20 2020 on patients previously
diagnosed with the emerging corona virus .. The study included 40 patients whose ages ranged from 20 to
80 years. The study also included taking 40 healthy people of the same age groups to detect interleukin 6
and 10 gamma interferon by using ELISA technique as well as measuring the level of the C-reactive protein.
The study contained a withdrawal of five ml of venous blood from patients and patients and took all the
necessary information from them such as gender, age, current living status, number of family members,
as well as the history of infection and travel to countries affected by the virus to compare the two groups
with regard to the immune response by measuring the variables above. The study showed that the highest
mean level of IL-6 was found in newly diagnosed COVID-19 patients comparing with healthy control
(60.76±8.46 v.s.39.03±5.26 pg/ml) (P:<0.01). The study also demonstrated that the level of IL-10 was
significantly elevated in newly diagnosed COVID-19 patients as compared with healthy control (38.18±4.57
v.s.31.84±3.19 pg/ml). The study established that the level of IFN-Gamma was significantly increased in
patients with new infection of COVID-19 as compared with healthy control (27.27±7.18 v.s. 13.81±3.83
pg/ml) (P:<0.01). The study proven that the level of CRP was increased significantly in patients with new
infection of COVID-19 as compared with healthy control (33.18±3.19 v.s.3.±1.81 mg/dl) (P:<0.01). The
study concluded that, There was a highly significant relation of IL-6, IL-0, IFN gamma, and CRP with
COVID-19 disease in the first week of infection
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.